Biocon has launched Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) in the US. Bosaya (biosimilar to Prolia) and Aukelso (biosimilar to Xgeva) are now available by prescription nationwide through specialty pharmacies and healthcare providers. Both products have been previously approved and granted interchangeable designation by the US Food and Drug Administration in September 2025, allowing substitution at the pharmacy level in accordance with state laws.

Shreehas Tambe, CEO and Managing Director, Biocon, said, “The US introduction of Bosaya and Aukelso marks a strategic expansion of our biosimilars portfolio, building on our established leadership in oncology and immunology. These therapies broaden access to high-quality, affordable treatment options for patients living with serious bone conditions. This milestone underscores Biocon’s strength as a portfolio development engine and our focus on building the world’s most scalable access platform—advancing life-changing medicines for patients and health systems across the United States and around the world.”

Denosumab products play a critical role in bone health, treating osteoporosis and bone complications associated with cancer. In 2024, denosumab products generated approximately USD 5 billion in US sales, reflecting the growing need for accessible treatment options.

While Bosaya will be available as 60 mg/mL injection for subcutaneous use in a pre-filled syringe, Aukelso will be 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial.